» » Recombinant Proteins, Monoclonal Antibodies & Therapeutic Genes

Download Recombinant Proteins, Monoclonal Antibodies & Therapeutic Genes fb2

by A. Mountain,U. M. Ney,Dietmar Schomburg
Download Recombinant Proteins, Monoclonal Antibodies & Therapeutic Genes fb2
Medicine & Health Sciences
  • Author:
    A. Mountain,U. M. Ney,Dietmar Schomburg
  • ISBN:
    3527283153
  • ISBN13:
    978-3527283156
  • Genre:
  • Publisher:
    Wiley-Blackwell; Volume 5a edition (April 15, 1999)
  • Pages:
    562 pages
  • Subcategory:
    Medicine & Health Sciences
  • Language:
  • FB2 format
    1769 kb
  • ePUB format
    1100 kb
  • DJVU format
    1341 kb
  • Rating:
    4.9
  • Votes:
    524
  • Formats:
    mbr docx lrf azw


oceedings{antPM, title {Recombinant proteins, monoclonal antibodies and therapeutic genes}, author {Andrew Mountain and Ulrich Ney and Dietmar Schomburg and Hans-J{"u}rgen Rehm and Gerald Reed}, year {1999} }. Andrew Mountain.

oceedings{antPM, title {Recombinant proteins, monoclonal antibodies and therapeutic genes}, author {Andrew Mountain and Ulrich Ney and Dietmar Schomburg and Hans-J{"u}rgen Rehm and Gerald Reed}, year {1999} }. Andrew Mountain, Ulrich Ney, +2 authors Gerald Reed. Structure of proteins protein engineering - novel properties genetically engineered proteins monoclonal antibodies beyond the proteins - replacement of proteins in therapy.

Start by marking Recombinant Proteins, Monoclonal Antibodies & Therapeutic Genes as Want to Read .

Start by marking Recombinant Proteins, Monoclonal Antibodies & Therapeutic Genes as Want to Read: Want to Read savin. ant to Read.

With the availability of tailored recombinant proteins and the opportunity to produce high amounts of monoclonal antibodies new diagnostic applications have emerged and many . A. Mountain, U. M. Ney, Dietmar Schomburg. Wiley, 19 Mar 1999 - 580 sayfa.

With the availability of tailored recombinant proteins and the opportunity to produce high amounts of monoclonal antibodies new diagnostic applications have emerged and many therapeutic perspectives, . in the treatment of multiple sclerosis and of cancer, are being discussed today. The aim of somatic gene therapy is to re-establish normal cell function by supplying the cells with the respective intact gene. This is a very difficult task and different diseases, .

Monoclonal antibodies (mAb or moAb) are antibodies that are made by identical immune cells that are all clones of a unique parent cell. Monoclonal antibodies can have monovalent affinity, in that they bind to the same epitope (the part of an antigen. Monoclonal antibodies can have monovalent affinity, in that they bind to the same epitope (the part of an antigen that is recognized by the antibody). In contrast, polyclonal antibodies bind to multiple epitopes and are usually made by several different plasma cell (antibody secreting immune cell) lineages

These have proven to be highly successful in treating inflammatory or autoimmune diseases, by blocking certain key molecules involved in the pathogenesis of the illness, cytokines (TNF) or immune coactivators (CTLA-4)

The therapeutic potential of monoclonal antibodies (mAb) was quickly realised after the hybridoma technique allowed their . Chimeric humanised and fully humanised mAb can now be made by recombinant engineering.

The therapeutic potential of monoclonal antibodies (mAb) was quickly realised after the hybridoma technique allowed their development in the mid 1970s. About a quarter of all biotech drugs in development are mAb, and around 30 products are in use or being investigated.

Home . Details for: Biotechnology, volume 5a, recombinant proteins, monoclonal antibodies and therapeutic genes : Normal view MARC view ISBD view.

In the field of medicinal biotechnology three major developments have caused a revolution in research that has a lot of innovative effects on clinical medicine and future applications on humans. With the availability of tailored recombinant proteins and the opportunity to produce high amounts of monoclonal antibodies new diagnostic applications have emerged and many therapeutic perspectives, e.g. in the treatment of multiple sclerosis and of cancer, are being discussed today. The aim of somatic gene therapy is to re-establish normal cell function by supplying the cells with the respective intact gene. This is a very difficult task and different diseases, e.g. AIDS and several metabolic disorders, are under investigation now. So far first promising approaches exist in cancer therapy. Moreover the book informs about regulatory and economic aspects of these new methods and their applications.